Back to search results

BRIDGE Study: Preventing Primary Graft Dysfunction After Lung Transplant

This study is investigating if the drug Anakinra can prevent primary graft dysfunction (a serious condition causing low blood oxygen and fluid in the lungs) in people receiving a lung transplant. Anakinra works by blocking a specific receptor (IL-1β) that contributes to inflammation. If you are 18 or older, planning to have a lung transplant using ex vivo lung perfusion (EVLP), and have not previously used an IL-1R antagonist drug, you might be able to join. Success in this study will be measured by how much primary graft dysfunction occurs three days after your lung transplant. The current status of this study is unclear, but it plans to enroll 20 participants.

Study design
This interventional study plans to enroll 20 participants who will be randomly assigned to either receive Anakinra or standard care. The study is not specified as blinded or open-label.
What's involved
Participants randomized to the treatment group will have one dose of Anakinra injected into the solution holding their donor lungs just before transplant. Both groups will receive standard lung transplant care after the procedure.
Compensation
Not stated in the trial record.
Follow-up
The primary outcome, primary graft dysfunction, is measured at 3 days post lung transplant.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07410312

BRIDGE - Blocking Receptor of IL-1β for Donor Graft Edema Reduction

Not Yet Recruiting
EARLY_PHASE1Ages 18+InterventionalTreatment
Northwestern University
~20 participants
Updated 2026-08-21 on ClinicalTrials.gov
What's tested:Anakinra

At a glance

Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Primary graft dysfunction after lung transplant
Measured over 3 days post lung transplant

Conditions

Lung Transplant Recipient

Explore related trials

Lung Transplantation

Where it's being run

1 sites across 1 states
Illinois1

Study leadership

  • Chitaru Kurihara, MD · PRINCIPAL_INVESTIGATOR · Northwestern University

Who to contact

Mary Carns, MS
[email protected]
312-503-1137
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Age 18 years or older.
Planning to undergo transplantation of the lung.
Willing and able to read, understand, and be capable of giving informed consent.
Use of ex vivo lung perfusion (EVLP) prior to lung transplant.

Exclusion

Previous or current use of IL-1R antagonist drug.
Any condition that, in the opinion of the attending physician, would place the patient at undue risk by participating, such as highly sensitized patients who require additional immunosuppression, multiorgan transplant, and re- transplant.

What this trial measures

  • Primary graft dysfunction after lung transplant3 days post lung transplant

    Occurrence of primary graft dysfunction after lung transplant on post-operative day 3, measured by arterial blood gas blood tests and chest X-rays.